CHECKPOINT THERAPEUTICS INC (CKPT) Stock Price, Quote, News and Overview
NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock
CKPT Quote and Key Statistics
CHECKPOINT THERAPEUTICS INC
NASDAQ:CKPT (1/21/2025, 8:00:00 PM)
Premarket: 2.99 -0.01 (-0.33%)3
-0.18 (-5.66%)
CKPT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -897.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CKPT Performance and Technical Analysis
CKPT Ownership and Analysts
CKPT Latest News and Analysis
Adoption of Autonomous Drones Rises for Military Operations Fueled by Cutting-Edge Technology
EQNX::TICKER_START (NASDAQ:ZENA),(NYSE:UAVS),(NASDAQ:RCAT),(NASDAQ:ONDS),(NASDAQ:DPRO),(CSE:DPRO),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring...
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.
About CKPT
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The firm is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Company Info
CHECKPOINT THERAPEUTICS INC
95 Sawyer Road, Suite 110
Waltham MASSACHUSETTS 10014 US
CEO: James F. Oliviero
Employees: 23
Company Website: https://checkpointtx.com/
Investor Relations: https://ir.checkpointtx.com
Phone: 17816524500
CKPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |